Keros Therapeutics (KROS) Change in Account Payables: 2019-2025
Historic Change in Account Payables for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$3.0 million.
- Keros Therapeutics' Change in Account Payables fell 85.62% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 338.69%. This contributed to the annual value of -$249,000 for FY2024, which is 115.43% down from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' Change in Account Payables is -$3.0 million, which was down 116.01% from -$1.4 million recorded in Q2 2025.
- Keros Therapeutics' Change in Account Payables' 5-year high stood at $4.7 million during Q2 2022, with a 5-year trough of -$5.0 million in Q3 2022.
- Over the past 3 years, Keros Therapeutics' median Change in Account Payables value was -$182,000 (recorded in 2023), while the average stood at -$85,364.
- As far as peak fluctuations go, Keros Therapeutics' Change in Account Payables slumped by 774.73% in 2024, and later surged by 8,678.26% in 2025.
- Over the past 5 years, Keros Therapeutics' Change in Account Payables (Quarterly) stood at $823,000 in 2021, then declined by 27.70% to $595,000 in 2022, then skyrocketed by 75.46% to $1.0 million in 2023, then slumped by 128.07% to -$293,000 in 2024, then crashed by 85.62% to -$3.0 million in 2025.
- Its Change in Account Payables was -$3.0 million in Q3 2025, compared to -$1.4 million in Q2 2025 and $2.0 million in Q1 2025.